Business, Free News Articles, NonProfit and Charities, Product Launches

Leading Healthcare-Associated Infection Clostridioides difficile Symposium Focuses on Patients, Families, and Caregivers

TAMPA, Fla. -- C Diff Foundation announced today that the Inaugural Patient, Family, and Caregiver C. diff. Live Virtual Symposium will be hosted on November 23, 2020 at 1 p.m.-4 p.m. EST with keynote topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia. The event is complimentary with online registration http://www.cdifffoundation.org/

Presenters will deliver data and discuss critical information for an audience of individuals diagnosed and recovering from a C. difficile infection. The symposium was developed to increase awareness, expand the knowledge, and elevate advocacy skills through presentations focused on a leading Healthcare-Associated Infection (HAI) Clostridioides difficile Prevention, Treatments, Clinical Trials, Diagnostics, and Environmental Safety for Adults and Children.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the Sponsor of the Patient and Family Symposium and for partnering with the C Diff Foundation raising C. diff. awareness.

Seres Therapeutics partners with the C Diff Foundation to support this important event focused on the patients and their families who are so deeply affected by this devastating infection.

The C diff Foundation's Founding President, Executive Director, Nancy C. Caralla, a three-time C. diff. Survivor, devotes countless hours day in and day out with the members of the C Diff Foundation. As a global resource, the members of the C Diff Foundation are doing all that they can to support the educational needs of patients worldwide. It is through episodes on C. diff. Spores and More live broadcasts, the annual Symposium, and Conference that give a voice to the patients who have suffered through multiple recurrences by including these speakers in the section of the program entitled "Survivor's Journey." Only through the patient's eyes can we begin to truly understand their experiences, and the unmet needs.

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About Seres Therapeutics:

Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, Microbiome, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook

Twitter @cdiffFoundation #Cdiffpatientsfamily2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/20-1119s2p-cdiff-symposium-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities

2020 International Clostridioides difficile (C. diff., C. difficile) Virtual Conference and Health EXPO Nov. 14

TAMPA, Fla. -- C Diff Foundation announced today that the 8th Annual International C. diff. Virtual-Online Conference and Health EXPO will be a 5-1/2 hour online program with over fourteen international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile, Gut Microbiome, Infection Prevention, and global healthcare-associated issues on November 14, 2020 with a live online program under the direction of IT professionals at WhiteHat Communications.

To learn more about this extraordinary conference, guest speakers, poster presentations, and the diverse topics being presented visit: https://cdiff2020.com/guest-speakers-1

All attendees will have the highest levels of online networking and learning opportunity at the Conference and Health EXPO and registration is complimentary this year. Save the date: November 4th and 5th, 2021 the 9th Annual conference will be hosted at the Boston Logan Hilton Hotel in Boston, Mass.

C Diff Foundation expresses their gratitude to Seres Therapeutics for being the conference Diamond Sponsor. Seres Therapeutics is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by a medical educational Grant from Pfizer and the members of the C Diff Foundation are profoundly grateful.

Attendee Paul Feuerstadt, MD, FACG, AGAF stated "The level of detail and data presented has a wonderful balance for those with an interest in the scientific research and interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

"I am excited to virtually meet and interact with everyone for the online extraordinaire C difficile foundation 2020 meeting. We will discuss all things C difficile and remember to tune in for my talk on the excitement of microbiome therapeutics for recurrent C difficile," stated Sahil Khanna, M.B.B.S., M.S.

The scientific data will be delivered through live virtual presentations and poster presentations at the 8th Annual International C. diff. Virtual Conference and Health Expo https://cdiff2020.com which coincides with the proclaimed; "November is Clostridioides difficile (C. diff., C. difficile) Awareness Month."

Scott Battles, VP of the C Diff Foundation stated, "We are profoundly grateful to the United States Governors for supporting our mission, along with our domestic and international partners."

November 18 - 24, 2020 Be Antibiotics Aware, a CDC educational effort, complements U.S. Antibiotic Awareness Week by providing partners with up-to-date information to help improve human antibiotic prescribing and use in the United States.

"None of us can do this alone, all of us can do this together."

About Clostridioides Difficile Infection (CDI)

Clostridioides (formerly Clostridium) difficile, also known as C. difficile or C. diff., is one of the most common causes of healthcare-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the United States and is associated with approximately 20,000 deaths. (Guh, 2020, New England Journal of Medicine). Based on internal estimates including a recurrence rate of approximately 20%, we believe the annual incidence in the U.S. approaches 600,000.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide.

Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (www.cdiffradio.com) sponsored by Clorox Healthcare.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Download "C diff and You" app from Apple and Google Stores.

Twitter @cdiffFoundation #Cdiff2020

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

IMAGE LINKS FOR MEDIA:

[1] https://www.Send2Press.com/300dpi/30-1111s2p-cdiff8th-splash-300dpi.jpg

[2] https://www.Send2Press.com/300dpi/20-1111s2p-Cdiff640-920Conf-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Business, Free News Articles

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif. -- The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week. From close to 2900 posters, only roughly 10% were selected as outstanding posters.

Progenabiome will also present a second poster: "Detection and Mutational Analysis of SARS-CoV-2 From Patient Fecal Samples by Whole Genome Sequencing." The ACG 2020 Meeting will be held virtually on October 23-28, 2020, and both poster abstracts and presentations will be available online in the ACG 2020 ePoster Hall.

Last year, Dr. Sabine Hazan, CEO of Progenabiome, shared groundbreaking data on C.Diff discovered through genetic sequencing at the 2019 ACG Meeting. She is looking forward to sharing newly found data on C.Diff and also COVID-19 at this year's event.

Dr. Hazan also recently published new findings from a phase 2 trial on Eosinophilic Gastritis and Duodenitis in the New England Journal of Medicine (NEJM.) As a leading clinical trials investigator who has overseen more than 150 clinical trials, Dr. Hazan is dedicated to research and producing validated, verified, and reproduced data.

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, Progenabiome has 41 ongoing clinical trials related to immunity and disease, including five COVID-19 studies validating testing, prophylaxis, and at-home treatment protocols for the novel coronavirus.

For more information, visit:
https://progenabiome.com

https://clinicaltrials.gov

https://malibumicrobiomemeeting.com/

ACG ePoster Hall: https://eventscribe.com/2020/ACGPosters/

NEJM paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2012047

Media Contact:
Stephanie Davis
sdavis@progenabiome.com

*IMAGE Link for Media: https://www.Send2Press.com/300dpi/20-1026s2p-Progenabiome-data-300dpi.jpg

Related link: https://progenabiome.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplant

VENTURA, Calif. -- Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).

After experiencing recurrent C.diff Infection (CDI) following hospitalization for pneumonia, the patient sought the expertise of Dr. Hazan, a gastroenterologist and microbiome expert. Since the patient previously failed several courses of antibiotics for CDI, with relapse confirmed via symptom recurrence and positive stool test, Dr. Hazan presented the option of fecal transplant (FMT). FMT involves the transfer of stool from a healthy individual to deliver healthy microbes to the gut of an ill patient. FMT can be used to treat CDI not responsive to standard therapies.

After a detailed discussion regarding the potential risks and benefits associated with the procedure, the patient underwent a single 300 mL FMT infusion using stool from his 85-year-old wife as a donor. At the time, the patient had scored 20 on his most recent Mini-Mental State Examination (MMSE) administered by a neurologist, indicating mild cognitive impairment. The patient's wife, on the other hand, was intellectually acute, with normal affect and stable mood.

Following the procedure, the patient's CDI symptoms resolved, and repeat stool testing two months later was negative. Additionally, the patient's wife reported improvements in his mental acuity and affect at the follow-up visit two months post-FMT. The MMSE was re-administered by the gastroenterologist and neurologist, and the patient scored 26, indicating normal cognition.

Four months post-FMT, the patient reported continued improvement in memory, with no progression in symptoms. The patient even remembered his daughter's birthday, which he was previously unable to recall. Six months post-FMT, the patient reported a marked improvement in mood, was more interactive, and showed more expressive affect. Readministration of the MMSE revealed that the patient's score had further increased to 29. The maximum MMSE score is 30 points.

Dr. Hazan is a specialist in gastroenterology, internal medicine and hepatology. She is the founder & CEO of ProgenaBiome, a genetic sequencing research laboratory dedicated to understanding the clinical implications of the microbiome.

"To our knowledge, this is the first report of a case of rapid symptom improvement of AD symptoms in a patient following FMT for recurrent CDI," says Dr. Hazan. "Based on the findings of this case and the analysis of the genetic sequencing of the gut flora, we will now submit an investigative new drug (IND) application for 20 additional Alzheimer's patients to undergo fecal transplant. We hope to reproduce this case and develop a stool marker that can help patients prevent Alzheimer's in the future."

While this case is a proof of concept for one patient, Dr. Hazan looks forward to expanding her work. She is currently seeking funding to expand the clinical trial for Alzheimer's improvement via FMT.

Dr Hazan also assembled the BIOME SQUAD, a group of her colleagues and fellow FMT doctors. The Biome Squad will be presenting data on the microbiome and fecal transplant at the Malibu Microbiome Meeting.

There will be a Virtual Prelude Rerun on October 14, 4 p.m. PT/PDT. For details and registration, visit: https://malibumicrobiomemeeting.com/

Read the full Alzheimer's report: https://journals.sagepub.com/doi/10.1177/0300060520925930

Interviews / Investors, Contact: Stephanie Davis, sdavis@progenabiome.com

Support ongoing research: https://microbiomeresearchfoundation.com/

About ProgenaBiome:

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, ProgenaBiome has 42+ ongoing clinical trials related to immunity and disease with six COVID-19 studies validating testing, prophylaxis, and treatment protocols for the novel coronavirus.

For more, visit https://progenabiome.com

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/20-1006s2p-malibu-microbiome-300dpi.jpg

Caption: Malibu Microbiome Meeting poster.

Related link: https://progenabiome.com/

This news story was published by the Neotrope® News Network - all rights reserved.